Universal GLP‑1s Slash Obesity Rates

Using national BMI distributions (NHANES) and one‑year weight‑loss effects from STEP‑1 (semaglutide), SURMOUNT‑1 (tirzepatide), and retatrutide phase 2, the author estimates how much U.S. obesity would fall if all adults used GLP‑1 drugs. The model adjusts for sex‑specific responses and suggests a rapid, sizable drop in obesity is feasible within a year. It also argues household drug costs could be modest if prices approach $15–$40/month. — This frames a concrete, near‑term policy option—subsidizing or broadly covering GLP‑1s—to treat obesity as a population‑level condition rather than lifestyle alone, with budget and equity implications.